Frontlight ResearchEarly access
Taking peopleNo phase
The Feasibility Study of Polymer Artificial Heart Valve for the Treatment the Mitral Valve Disease.
Key facts
- Who runs it
- Shanghai HeartEpoch Medical Technology Co., Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 10 people, planned
- Started
- 19 Nov 2025
- Expected to end
- Nov 2032
- Type of study
- Interventional
- Treatments tested
- mitral valve replacement
- Record updated
- 6 July 2026
Who can take part
- Age
- 60 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- ≥ 60 years old
- severe mitral regurgitation or severe mitral stenosis confirmed by ECHO
- surgical mitral valve replacement
Who cannot take part
- History of cardiac surgery or history of cardiac intervention( within 1 year), Concurrent cardiac surgery(excluding tricuspid valve repair surgery or atrial fibrillation ablation) or cardiac interventional procedures
- Severe macrovascular lesions require surgical treatment
- There was evidence of acute myocardial infarction within 1 month before the surgery (Q-wave MI or non-Q-wave MI, CK-MB ≥ twice the normal level and/or elevated troponin);
- here was a history of cerebrovascular events (CVA) within 1 month before the surgery, including ischemic and hemorrhagic strokes, but excluding transient ischemic attacks (TIA)
- Coronary artery disease that requires revascularization;
- Patients with active bleeding, bleeding tendencies or those who are unable to receive anticoagulant therapy;
- Confirmed or suspected diagnosis of infective endocarditis or other active infections
- There are diseases that significantly affect the evaluation of treatment, such as patients with neurological disorders that affect cognitive abilities, and patients with malignant tumors and an expected lifespan of no more than one year;
- LVEF < 50%
- STS ≥8;
- intracardiac mass, thrombus or neoplasm confirmed by echo
- A pacemaker need to be implanted
- Other situations in which patients are not suitable to participate in this trial
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study aims to evaluate the feasibility and safety of polymer artificial heart valve designed and developed by Shanghai HeartEpoch Medical technology Co. Ltd. for the treatment of the mitral valve diseases.
The group in the trial
- Polymer Artificial Heart ValveTreatment being tested
Device: Polymer Artificial Heart Valve Mitral valve replacement
Treatment: mitral valve replacement
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multicenter Clinical Trial Evaluating the Feasibility and Safety of Polymer Artificial Heart Valve for the Treatment of Mitral Valve Diseases
- Record updated
- 6 July 2026